We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Angle Plc | AGL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 3.25 | 26.53% | 15.50 | 15:48:16 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 14.75 | 14.50 | 17.35 | 15.50 | 12.25 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 24/4/2024 12:41 by bones698 More fda clearances. Cellkeep sales, PDL1 and hers 2 kit sales, pharma services business increasing etc etc. The interesting part is recurring and increasing revenue for many years to come. The market is missing that along with investors. |
Posted at 10/4/2024 10:51 by robizm Non starter as Angle is owned by private investors |
Posted at 07/3/2024 17:03 by bones699 Unfortunately that's the reality here Newland sold an empty dream to investors.If you recall at the Investor Meet in London back in January when asked about FDA approval...Newland replied by saying that Parsortix could be used for testing other cancers than breast cancer so long as the laboratory concerned seeks accreditation from the FDA to do so. ...at which point I nearly fell out of my chair.. ..Its bit like a car salesman saying to a would be buyer the new car can be used for going up to speeds of 10 mph in first and second gears only but if you want it go much faster you need to apply to the NCAP 'New Car Assessment Program' to ensure the vehicle meets all the stringent safety points and regulations! Hence why Parsortix has had zero commercial deals signed to date. |
Posted at 27/2/2024 20:38 by bones699 It's very pertinent to discuss the funding issue as cash balances must surely be just £8m or £9m at most..Cash in June 2023 was £20m with monthly cash burn £1.5m now 7 months on cash is dwindling fast maybe just 6 months left before a cash raise will need to be raised..Newland promised £6m of additional revenues to date nothing delivered and time is marching on as to the 'strategic initiatives' in case cash dried up with no commercial deals in the offing these were just washed over at January's Investor Meet basically fobbing off retail investors...Its looking like another retail drive by mugging by Newland! I reckon we will hear a £20m cash raise announced during Q2 and no later than Q3! |
Posted at 22/1/2024 22:07 by bones699 The Edison Theranos machine comparison is a good comparison to Parsortix why is the CEO at the Investor Meet ramping a testing machine that is far away from being fully approved by the FDA and is reliant on third party machines..You simply can't use Parsortix to test any cancer other than breast cancers so why when asked by an Investor he states you can use it if you have a 'handle on it to test for other cancers so long as you are an accredited lab'...Nonsense the correct answer is 'No you can't use Parsortix to test cancers other than for testing breast cancer'.. So why the waffle when answering the Investors very pertinent question! And why did that women monitoring questions as soon as he asked about FDA approval try and forcefully seize the mick out of his hand...Anything you would like to add Newland? |
Posted at 17/1/2024 13:16 by mrkeysersoze Well if that presentation doesn’t attract new investors, existing investors increase / average down or simply sit on your hands I give up…..Fantastic presentation…. Well done AN & Team Angle. Mr K. |
Posted at 17/1/2024 08:23 by bones699 Nobby.So why no financials slides in the Investor Meet with a slide on forecasted revenues, earnings, expected breakeven, and cash runway then? Answer Newland has no confidence in them and doesn't want to be held to account when later in the year they don't get delivered.. Some Investor Meet without any financials to judge the investment case! Might as well just chuck a coin in the air! And how much retail investors money have AGL burnt through in the years trading to date £200m is it? |
Posted at 12/1/2024 13:37 by bones699 From the LSE BB seems like a smart guy.TwoGood2Die Posts: 1,391 Price: 17.75 No Opinion Day Traders Getting Desperate Today 13:24 I did advice that the share price would retrace back to where it started based on the following. No financials on expected revenues, profits and timelines provided! No cash run way provided and out to when! No details on expected contract wins and likely dates! No confirmation of the test results meeting the FDA minimum requirements for Parsortix roll out. No Director Buys and Virtually No Instutional Investor Buys apart from a paltry 1% from an existing stakeholder. Ergo the Investor Presentation was more carefully drafted 'Smoke and Mirrors' and basically all 'Hype' and very 'Vague' and didn't address investor's concerns and issues! Think about it jump forward six months to a year from now is there anything in that Investor Presentation from yesterday that you could hold the Directors to account, nano, zilch, nothing! |
Posted at 10/1/2024 23:26 by 5oletrader (Addition to my last post) Institutional Investors often have SPECIFIC PREFERENCEs that they would like to convey to the COMPANIES in their portfolio. Investors have various mechanisms for INFLUENCING COMPANIES.- Global Frontier Investments LLC - Holds AGL & Accenture (ACN). ACN works closely with ROCHE. Remember the word - INFLUENCE.-I note this guy Maxim Lewinz is employed by ACN - involved in their Life Science Strategy. He published a piece on 8th JAN24 titled: WILL 2024 BE A LEAP YEAR FOR LIQUID BIOPSY?-"LIQUID BIOPSY going MAINSTREAM may have several IMPLICATIONS that BIOPHARMA companies are already STARTING to PREPARE for." This includes: To Consider PARTNERING with select LIQUID BIOPSY COMPANIES to build competitive advantage, e.g., in developing targeted oncology products.-FUNDs from FINANCIAL INVESTORs are pouring into companies like Guardant Health, Natera and ILLUMINA, reflecting a BULLISH SENTIMENT around the LIQUID BIOPSY MARKET. This is fueled by several factors: Increasing SUPPORT from REGULATORS, most importantly demonstrated by FDA's 2022 guidance document "Use of Circulating Tumor DNA for Early-Stage Solid Tumor Drug Development" INCREASING number of oncology TRIALS using LIQUID BIOPSY Upcoming LAUNCH of multiple KEY PRODUCTs-Article here:https://www.lin |
Posted at 26/11/2023 17:51 by 5oletrader One for the diary? Plugging AGL to US investors.I note this coming week on Thursday 30th Nov at 17:00GMT - AGL will be presenting at the Small Cap Growth Virtual Investor Conference.https://w |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
